Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6244 vs temozolomide in unresectable stage 3 or 4 malignant melanoma
2006-001456-12Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selumetinib in melanoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Primary efficacy comparison and Safety and tolerability of AZD6244. Started Mar 2006; status: completed.
02
Drugs
selumetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2006-001456-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001456-12.